greater export sales portion. 3. In Q3 2017, the Company and its subsidiaries recorded the assets’ impairment loss and write- off of Solvay Biochemicals (Taixing) Limited (“SBT”) net amounting to 132 MB

: Price depending on the actual negotiated transaction prices between the buyer and seller (Referring to the book value as of December 31, 2016 at Baht 150.89 per share) Summary of financial statements

Exchange of Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the three-month period at the end of 31st March 2019 as follows. Summary

( 2 ) aspx ( 1 ) http://172.19.1.196:8983/solr/secweb/select?q=สินทรัพย์ดิจิทัล OR "Digital assets" OR "Digital properties"&wt=json&indent=true&facet=true&facet.field=key_filetype&facet.field

Dental Public Company Limited (LDC) would like to clarify the performance of the Company for the 6 months period ended June 30, 2018 which the details are as followed: Summary of the Company’s Performance

Limited Page 6/12 Summary of Consolidated Financial Results 31 March 31 December Assets 2019 2018 + (-) % (in thousand Baht) Current assets Cash and cash equivalents 165,526 258,184 (56%) Temporary

137 MTHB from 2018 due to higher distribution costs from higher export portion, plus loss from unused assets disposal. 3. In October 2019, the Company completed the dissolution of Vinythai Holding Pte

summary of the Company’s operating performance in the first quarter of 2018 and 2017 is shown in the following table: 1Q18 4Q17 % Change 1Q17 % Change [Amount in Baht Million] Q-o-Q Y-o-Y [1Q18VS 4Q17

summary of the Company’s operating performance in the second quarter of 2017 and 2016 is shown in the following table: 2Q17 1Q17 %Change 2Q16 %Change [Amount: in Baht Million] Q-o-Q Y-o-Y [2Q17 VS. 1Q17

. A summary of the Company’s operating performance in the third quarter of 2017 and 2016 is shown in the following table: 3Q17 2Q17 %Change 3Q16 %Change [Amount: in Baht Million] Q-o-Q Y-o-Y [3Q17 VS